Telix Pharmaceuticals (OTCMKTS:TLPPF – Get Free Report) is expected to release its results before the market opens on Friday, February 20th. Analysts expect Telix Pharmaceuticals to post earnings of $0.0328 per share and revenue of $322.8750 million for the quarter.
Telix Pharmaceuticals Price Performance
Shares of OTCMKTS:TLPPF opened at $6.61 on Friday. Telix Pharmaceuticals has a 1-year low of $6.15 and a 1-year high of $24.85. The business has a 50-day moving average price of $7.77 and a two-hundred day moving average price of $9.41.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
Recommended Stories
- Five stocks we like better than Telix Pharmaceuticals
- Free: The Crypto Summit That Could Change Your Life
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Your Bank Account Is No Longer Safe
- When to buy gold (mathematically)
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
